Partial inhibition of the ubiquitin–proteasome system ameliorates cardiac dysfunction following ischemia–reperfusion in the presence of high glucose by unknown
Adams et al. Cardiovasc Diabetol  (2015) 14:94 
DOI 10.1186/s12933-015-0258-4
ORIGINAL INVESTIGATION
Partial inhibition of the ubiquitin–
proteasome system ameliorates cardiac 
dysfunction following ischemia–reperfusion 
in the presence of high glucose
Buin Adams, Rudo F Mapanga and M Faadiel Essop*
Abstract 
Background: Acute hyperglycemia co-presenting with myocardial infarction (in diabetic and non-diabetic individu-
als) is often associated with a poor prognosis. Although acute hyperglycemia induces oxidative stress that can lead to 
dysregulation of the ubiquitin–proteasome system (UPS), it is unclear whether increased/decreased UPS is detrimen-
tal with ischemia–reperfusion under such conditions. As our earlier data implicated the UPS in cardiac damage, we 
hypothesized that its inhibition results in cardioprotection with ischemia–reperfusion performed under conditions 
that simulate acute hyperglycemia.
Methods: Ex vivo rat heart perfusions were performed with Krebs–Henseleit buffer containing 33 mM glucose vs. 
controls (11 mM glucose) for 60 min stabilization, followed by 20 min global ischemia and 60 min reperfusion ± 5 µM 
lactacystin and 10 µM MG-132, respectively. The UPS inhibitors were added during the first 20 min of the reperfu-
sion phase and various cardiac functional parameters evaluated. In parallel experiments, infarct sizes were assessed 
following 20 min regional ischemia and 120 min reperfusion ± each of the respective UPS inhibitors (added during 
reperfusion). Heart tissues were collected and analyzed for markers of oxidative stress, UPS activation, inflammation 
and autophagy.
Results: The proteasome inhibitor doses and treatment duration here employed resulted in partial UPS inhibi-
tion during the reperfusion phase. Both lactacystin and MG-132 administration resulted in cardioprotection in our 
experimental system, with MG-132 showing a greater effect. The proteasome inhibitors also enhanced cardiac 
superoxide dismutase protein levels (SOD1, SOD2), attenuated pro-inflammatory effects and caused an upregulation 
of autophagic markers.
Conclusions: This study established that partial proteasome inhibition elicits cardioprotection in hearts exposed 
to ischemia–reperfusion with acute simulated hyperglycemia. These data reveal that protease inhibition triggered 
three major protective effects, i.e. (a) enhancing myocardial anti-oxidant defenses, (b) attenuating inflammation, and 
(c) increasing the autophagic response. Thus the UPS emerges as a unique therapeutic target for the treatment of 
ischemic heart disease under such conditions.
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Background
The link between hyperglycemia and increased mor-
bidity/mortality with heart diseases such as acute myo-
cardial infarction (AMI) is receiving growing attention 
[1–3]. Hyperglycemia can manifest as a more chronic 
condition (typically found with diabetes) or as a stress-
induced state, e.g. in diabetic and non-diabetic per-
sons challenged by an AMI. Chronic hyperglycemia 
may sometimes be linked to the development of mac-
rovascular complications [4], with AMI the chief con-
tributor to cardiovascular mortality with diabetes [5–7]. 
Acute, stress-induced hyperglycemia is associated with 
increased in-hospital deaths, congestive heart failure, 
and cardiogenic shock [8–10]. The presentation of hyper-
glycemia in non-diabetic individuals likely represents a 
combination of undiagnosed diabetes, impaired glucose 
tolerance [11, 12], and a robust response to acute stress 
[8, 9].
Hyperglycemia-induced oxidative stress can lead to 
the formation of misfolded or damaged proteins that are 
usually eliminated by the ubiquitin–proteasome system 
(UPS), the major role player responsible for non-lysoso-
mal protein degradation [13, 14]. However, a dysfunc-
tional UPS is linked with a pro-inflammatory milieu 
and impaired cardiac function in diabetic mice [15] 
and diabetic patients presenting with unstable angina 
[16]. Although altered UPS functioning is implicated 
with diminished cardiac function, it remains unclear 
whether greater or lesser UPS activation is detrimental 
with ischemia–reperfusion under such conditions. This 
conundrum also applies for UPS regulation in response 
to ischemia–reperfusion per se, i.e. under normoglyce-
mic conditions. For example, some found that oxidative 
stress, inflammation and myocardial reperfusion injury 
can be blunted by proteasomal inhibitor treatment [15, 
16]. Furthermore, UPS inhibition leads to a reduction in 
ventricular tachyarrhythmias [17] and preserved cardiac 
function following myocardial ischemia under baseline 
glucose conditions. Conversely, others established that 
UPS inactivation (due to oxidative damage occurring 
with ischemia–reperfusion) is a robust contributor to 
the damaging effects elicited by an AMI [18]. Such dis-
cordant findings may be due to different experimental 
protocols/models utilized and due to variations in UPS 
inhibitor class, dosages and length of administration [19, 
20]. With the paucity of studies investigating UPS regu-
lation with ischemia–reperfusion under acute hypergly-
cemic conditions, efforts to gain greater insight into this 
intriguing question are essential as it will contribute to 
(a) the delineation of underlying mechanisms, and (b) the 
development of novel cardioprotective agents.
As our earlier findings implicated increased UPS acti-
vation in hyperglycemia-mediated cardiac damage [21] 
we hypothesized that its inhibition during early reperfu-
sion provides cardioprotection following ischemia–rep-
erfusion under high glucose conditions. We employed 
an established rat model of ex vivo isolated heart perfu-
sions subjected to ischemia–reperfusion and exposed 
to simulated acute hyperglycemia as before [21, 22]. To 
further strengthen these data two different UPS inhibitor 
classes were used, i.e. lactacystin (2-(acetylamino)-3-[({3-
hydroxy-2-[1-hydroxy-2-methylpropyl]-4-methyl-5-ox-
opyrrolidin-2-yl}carbonyl)sulfanyl]propanoic acid) and 
MG-132 (N-(benzyloxycarbonyl) leucinylleucinylleucinal 
Z-Leu-Leu-Leu-al). The current study demonstrates that 
proteasome inhibition elicits cardioprotection in hearts 
exposed to ischemia–reperfusion with acute simulated 
hyperglycemia by upregulating anti-oxidant defenses, 




All animals were treated in accordance with the Guide for 
the Care and Use of Laboratory Animals of the National 
Academy of Sciences (NIH publication No. 85-23, revised 
1996). This study was carried out with the approval of the 
Animal Ethics Committee of Stellenbosch University.
Ex vivo perfusion protocol
Male Wistar rats weighing 180–220 g were used for this 
study. Rats were anesthetized (pentobarbitone, 100  mg/
kg i.p.) and hearts rapidly excised and perfused in a 
modified Langendorff model as described before [21, 
22]. Briefly, Krebs–Henseleit buffer containing (in mM) 
11 glucose, 118 NaCl, 4.7 KCl, 1.2 MgSO4·7H2O, 2.5 
CaCl2·2H2O, 1.2 KH2PO4, 25 NaHCO3 was equilibrated 
with 95% O2–5% CO2 (37°C, pH 7.4) at a constant pres-
sure (100 cm). Buffer was not recirculated and the hearts 
were allowed to beat at their natural rate. During perfu-
sion, a latex balloon attached to a pressure transducer 
(Stratham MLT 0380/D, ADInstruments Inc, Bella Vista, 
NSW, Australia) compatible with the PowerLab System 
ML410/W (ADInstruments Inc, Bella Vista, NSW, Aus-
tralia) was inserted into the left ventricle via the mitral 
valve and inflated to produce a systolic pressure of 
80–120 mmHg and a diastolic pressure of 4–12 mmHg. 
The temperature of the heart was maintained at 37°C by 
suspending it in a heated water jacket.
The protocol was divided into two parts, i.e. perfusions 
(a) with global ischemia and (b) regional ischemia, fol-
lowed by reperfusion for cardiac functional assessments 
and infarct size determination, respectively. For each of 
these, hearts were randomly distributed into six experi-
mental groups for perfusions: baseline control (11  mM 
glucose) ±  either 5 μM lactacystin or 10 μM MG-132; 
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and high glucose (33 mM glucose) ± either 5 μM lacta-
cystin or 10 μM MG-132 (n = 8 rats were used for each 
of the experimental groups indicated). The respective 
UPS inhibitors (lactacystin, MG-132) were dissolved in 
the buffer and added for the first 20 min of reperfusion.
For our inhibition studies we aimed to achieve so-called 
“non-toxic proteasome inhibition’’, i.e. only partial attenu-
ation of chymotrypsin-like activity as high and sustained 
doses can result in severe toxic effects with detrimental 
outcomes [23]. Lactacystin is a natural compound that 
binds mainly to the β5 proteasomal subunit (responsi-
ble for chymotrypsin-like activity) of the 20S proteasome 
[24], leading to irreversible inhibition of chymotrypsin-
like activity (reviewed in [25]). However, the trypsin- and 
caspase-like activities are blunted to a lesser extent in this 
instance [26]. We also employed the reversible aldehyde 
inhibitor MG-132 that specifically binds to proteasomal 
subunit β5 of the 20S proteasome (reviewed in [25]). Pro-
teasome inhibitor doses were selected to be in the range 
of what was employed in previously published studies 
[27, 28]. High glucose perfusions were used to simu-
late acute hyperglycemia and since ex  vivo Langendorff 
perfusions are typically performed with 11  mM glucose 
at baseline, the 33 mM dose would be representative of 
a threefold elevation of glucose levels (above normal) 
within the clinical setting. Additional experiments were 
also performed in order to rule out the effects of osmotic 
pressure on heart function. Here rat hearts were perfused 
with 22 mM mannitol plus 11 mM glucose (total molar-
ity = 33 mM) and subjected to ischemia–reperfusion as 
described above.
Ex‑vivo global ischemia and reperfusion
The protocol included a 60  min stabilization period, 
20  min of global ischemia, followed by 60  min of rep-
erfusion. Contractile parameters assessed throughout 
the experiment included heart rate (HR), left ventricu-
lar developed pressure (LVDP), end diastolic pressure 
(EDP), rate-pressure product (RPP = HR × LVDP), and 
coronary flow. The percentage recovery for LVDP and 
RPP was also calculated where reperfusion data points 
were expressed as a percentage of pre-ischemic values. 
Coronary flow was measured by collection of the effluent 
at regular timed intervals. Both left and right ventricu-
lar tissues were immediately collected after the 60  min 
reperfusion period with tissues freeze-clamped in liquid 
nitrogen with pre-cooled Wollenberger tongs, whereaf-
ter it was stored at −80°C for further molecular and bio-
chemical analyses.
Ex‑vivo regional ischemia and reperfusion
To further strengthen our Langendorff functional data, 
we also evaluated the effects of lactacystin and MG-132 
by infarct size determination. This was performed as 
described before [21, 22], and we employed regional 
ischemia with a reperfusion time of 2 h. Here a 3/0 silk 
suture was placed on the proximal portion of the left 
anterior descending coronary artery and passing the 
ends through a plastic tube. For induction of regional 
ischemia the ends were tightened by pressing the plastic 
tube against the surface of the heart (above the artery) 
for 20  min. The snare was released during the reperfu-
sion period. The efficacy of ischemia was confirmed by 
regional cyanosis and a substantial decrease in coronary 
flow.
After completion of each regional ischemia–reperfu-
sion experiment the snare was re-tightened and 2.5% 
Evans blue dye (in Krebs buffer) was perfused through 
the hearts for identification of the area at risk of ischemia. 
Hearts were subsequently removed from the Langendorff 
apparatus, blotted dry, suspended (using suture) within 
50 ml plastic tubes and frozen at −20°C for 3 days. Fro-
zen hearts were thereafter sliced into 2  mm transverse 
sections and incubated with 1% 2,3,5-triphenyl tetrazo-
lium chloride in phosphate-buffered saline for 20  min 
at 37°C. Slices were then fixed in 10% formalin for 24 h 
at room temperature before being placed between glass 
plates for scanning. The infarct size and the area-at-risk 
were determined using Image J software (v1.46p, NIH, 
USA) and infarct size was expressed as a percentage of 
the area-at-risk.
Measurement of intracellular E3 ligases, oxidative stress, 
inflammation and autophagic markers
Protein isolation was performed as previously described 
[29]. Briefly, collected heart tissues were homogenized 
with modified RIPA buffer, the supernatant centrifuged 
twice at 4,300g for 10  min at 4°C then stored at −80°C 
until further use. Protein expression was determined by 
SDS-PAGE as described previously by our laboratory [21, 
29], and Western blotting performed with representa-
tive markers for: (a) E3 ligases; Muscle RING Finger 1 
(MURF1; Abcam, Cambridge, MA, USA) and muscle 
atrophy F-box (MAFbx; Santa Cruz Biotechnologies, 
Santa Cruz, CA, USA); (b) oxidative stress: superoxide 
dismutase 1 and 2 (SOD1, SOD2; Santa Cruz Biotech-
nologies, Santa Cruz, CA, USA); (c) inflammation: tumor 
necrosis factor-alpha (TNF-α; Sigma-Aldrich, St. Louis, 
MO, USA), and inhibitor of nuclear factor kappa-B kinase 
subunit alpha (IκBα; Sigma-Aldrich, St. Louis, MO, USA); 
and (d) autophagy: microtubule‐associated protein 1 light 
chain 3 II (LC3-II; Cell Signaling, Danvers, MA, USA), 
and p62 (Cell Signaling, Danvers, MA, USA). West-
ern blots were quantified by densitometric analysis and 
β-actin (Cell Signaling, Danvers, MA, USA) employed as a 
loading control as described before [21, 22].
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Proteasome activity experiments
Heart tissues were cut into small slices and homogenized 
in 1 ml of Tris–HCl buffer (pH 7.4) using an IKA Ultra 
Turrax T25 homogenizer (IKA Labortechnik, Staufen, 
Germany) and incubated on ice for 10  min before cen-
trifugation at 9,000g for 15  min to remove cell debris. 
The supernatant was employed for protein quantification 
using the Bradford assay as described previously [30].
Fig. 1 High glucose-induced cardiac contractile dysfunction independent of osmotic pressure. Isolated rat hearts were perfused under high glu-
cose conditions (33 mM glucose) vs. controls (11 mM glucose) for 60 min and thereafter subjected to 20 min of global ischemia, followed by 60 min 
of reperfusion. In parallel experiments, groups were similarly perfused under hyperosmotic conditions (22 mM mannitol + 11 mM glucose; 33 mM). 
a Left ventricular developed pressure (LVDP) (% recovery) under baseline conditions vs. mannitol control, b maximum ventricular contraction (dP/
dtmax) under baseline glucose conditions vs. mannitol control, c LVDP (% recovery) under high glucose conditions vs. mannitol control, d dP/dtmax 
under high glucose conditions vs. mannitol control, and e Infarct size/area at risk (%) under baseline, high glucose and hyperosmotic conditions 
after subjecting rat hearts to regional ischemia as described before. Values are expressed as mean ± SEM (n = 6). *p < 0.05, **p < 0.01 vs. respective 
controls.
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The Proteasome-Glo™ 3-Substrate System (Promega, 
Madison, WI, USA) consists of three homogeneous bio-
luminescent assays that separately measure the three 
proteolytic activities associated with the proteasome, 
i.e. chymotrypsin-like (LLVY), trypsin-like (LSTR), and 
caspase-like (LLE) activities. The three assays differ in 
their ability to detect different protease activities based 
on their substrate components, i.e. the luminogenic 
substrates provided for the LLVY, LSTR, and LLE are 
Suc-LLVY-aminoluciferin, Z-LRR-aminoluciferin, and 
Z-nLPnLD-aminoluciferin, respectively. Each substrate is 
added to a buffer system optimized for proteasome and 
luciferase activities to make a Proteasome-Glo™ Reagent 
for a particular catalytic activity. The individual Proteas-
ome-Glo™ Reagent is added to test samples in an “add-
mix-measure” format, resulting in proteasome-induced 
cleavage of each particular substrate. Substrate cleavage 
generates a “glow-type” luminescent signal produced by 
the luciferase reaction that is proportional to proteasome 
activity.
Assays were performed with ~50 µg of protein lysate [in 
25 mM Tris–HCl (pH 7.5)] together with the respective 
substrate—incubated together for 30 min at 37°C. Ami-
nomethylcoumarin and β-naphthylamine luminescence 
Fig. 2 Lactacystin and MG-132 administration attenuate proteasomal activities during ischemia–reperfusion. Isolated rat hearts were perfused 
under high glucose (33 mM) conditions vs. controls (11 mM) and subjected to global ischemia and reperfusion as earlier described. For UPS inhibi-
tion, either 5 μM lactacystin or 10 μM MG-132 was added for the first 20 min of the reperfusion period. The respective proteasomal activities evalu-
ated: a, d trypsin-like (LSTR), b, e chymotrypsin-like (LLVY), c, f caspase-like (LLE). Values are expressed as mean ± SEM (n = 8). *p < 0.05, **p < 0.01, 
***p < 0.001 vs. respective controls.
Page 6 of 15Adams et al. Cardiovasc Diabetol  (2015) 14:94 
was subsequently measured using a luminometer micro-
plate reader (BMG Labtech, Ortenberg, Germany) and 
data were normalized to protein concentrations.
Statistical analysis
Data are presented as mean  ±  standard error of mean 
(SEM). Statistical analysis was performed by the Mann–
Whitney t-test, or one-way analysis of variance (ANOVA) 
followed by the Tukey–Kramer post hoc test (GraphPad 
Prism v5, San Diego, CA, USA). Values were considered 
significant when p < 0.05.
Results
To rule out the possibility of attributing the effects of 
hyperglycemia on heart function to changes in osmolar-
ity, separate perfusion experiments were completed with 
11  mM glucose plus 22  mM mannitol (total molarity 
33 mM). These data demonstrate no differences in LVDP 
recovery and dP/dtmax for the osmotic control group vs. 
hearts perfused under baseline glucose (11  mM) condi-
tions (Fig.  1a, b). By contrast, hearts exposed to high 
glucose displayed lower LVDP recovery compared to 
the osmotic control group (p < 0.05) with no differences 
for dP/dtmax (Fig.  1c, d). High glucose perfusions also 
resulted in greater infarct sizes compared to both control 
groups (p < 0.01) (Fig. 1e).
We next determined the effects of high glucose expo-
sure on post-ischemic UPS activities. Here trypsin-, chy-
motrypsin- and caspase-like activities were significantly 
upregulated (Fig. 2). The effects of lactacystin and MG-132 
were determined and both compounds—as expected—sig-
nificantly lowered myocardial chymotrypsin-like activity 
(Fig.  2). To further validate the degree of UPS inhibition 
we also assessed peptide levels of E3 ligases (MURF1 
and MAFbx) involved in the final step of the ubiquitina-
tion process. Here MAFbx expression was significantly 
Fig. 3 Decreased expression of E3 ubiquitin ligases during ischemia–reperfusion. Isolated rat hearts were perfused under high glucose conditions 
(33 mM glucose) vs. controls (11 mM glucose) for 60 min and subsequently subjected to 20 min of global ischemia, followed by 60 min of reperfu-
sion ± either 5 μM lactacystin or 10 μM MG-132 treatment for the first 20 min of reperfusion. Western blot analysis was completed for: a muscle 
RING finger 1 (MuRF1) and b muscle atrophy F-box (MAFbx) with lactacystin treatment; c MURF1 and d MAFbx with MG-132 administration. We 
employed β-actin as loading control. Values are expressed as mean ± SEM (n ≥ 4). *p < 0.05, **p < 0.01 vs. respective controls.
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increased under high glucose conditions, while both lacta-
cystin and MG-132 administration decreased MURF1 and 
MAFbx expression following ischemia–reperfusion under 
high glucose conditions (Fig. 3).
We next evaluated functional parameters in our experi-
mental system and found that high glucose exposure 
blunted cardiac contractile function vs. matched controls 
following ischemia–reperfusion (Figs. 4, 5). Acute lacta-
cystin administration during the reperfusion phase sig-
nificantly improved LVDP recovery at baseline (Fig.  4a) 
and also under high glucose conditions (from 10 ± 2.3% 
to 36 ± 4%; p < 0.01 vs. untreated high glucose) (Fig. 4c). 
RPP data exhibited a similar trend although lactacystin 
had no effect under baseline glucose conditions com-
pared to the untreated group (Fig. 4b). MG-132 elicited 
robust cardioprotection (LVDP, RPP) at baseline and in 
response to high glucose exposure (Fig.  5). Moreover, 
both lactacystin and MG-132 decreased end-diastolic 
pressure in hearts exposed to high glucose conditions, 
although there were no differences for the control groups 
(Table 1). Proteasome inhibitor treatment also enhanced 
coronary flow although this was only statistically signifi-
cant for MG-132 (p  <  0.05 vs. untreated high glucose) 
(Table  1). Our comparative analyses show that MG-132 
administration resulted in greater cardioprotection 
compared to lactacystin (Fig.  6). The regional ischemia 
experiments further support these findings by demon-
strating that lactacystin blunted the high glucose-induced 
increase in the infarct size/area-at-risk from 66.4 ± 3.4% 
to 48 ± 3.9% (p < 0.05 vs. high glucose untreated) (Fig. 7). 
Likewise, MG-132 treatment decreased infarct sizes 
under baseline and high glucose perfusion conditions. 
Fig. 4 Lactacystin administration improves contractile function during ischemia–reperfusion. Isolated rat hearts were perfused under high glucose 
conditions (33 mM glucose) vs. controls (11 mM glucose) for 60 min and thereafter subjected to 20 min of global ischemia, followed by 60 min of 
reperfusion. Lactacystin (5 μM) was added to treatment groups during the first 20 min of reperfusion. a Left ventricular developed pressure (LVDP) 
(% recovery) at baseline glucose levels (11 mM), and c with high glucose (33 mM). Rate pressure product (RPP) (% recovery) at baseline glucose 
levels (b), and d under high glucose conditions. Values are expressed as mean ± SEM (n = 8).*p < 0.05, **p < 0.01 vs. respective controls.
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Here MG-132 significantly attenuated the infarct 
size/area-at-risk to 40.3  ±  2.5% and 49.7  ±  7.4% vs. 
56.3 ± 2.8% and 73.5 ± 4.9% at baseline and high glucose 
perfusions, respectively. There were no differences in the 
area-at-risk for any of the experimental groups investi-
gated (data not shown).
Fig. 5 MG-132 administration improves contractile function during ischemia–reperfusion. Isolated rat hearts were perfused under high glucose 
conditions (33 mM glucose) vs. controls (11 mM glucose) for 60 min and thereafter subjected to 20 min of global ischemia, followed by 60 min of 
reperfusion. MG-132 (10 μM) was added to treatment groups during the first 20 min of reperfusion. a Left ventricular developed pressure (LVDP) (% 
recovery) at baseline glucose levels (11 mM), and c with high glucose (33 mM). Rate pressure product (RPP) (% recovery) at baseline glucose levels 
(b), and d under high glucose conditions. Values are expressed as mean ± SEM (n = 8). ***p < 0.001 vs. respective controls.
Table 1 Coronary flow, end-diastolic pressure (EDP) and heart rate (HR) under baseline vs. high glucose perfusion condi-
tions with ischemia–reperfusion
All values were recorded during the first 10 min of stabilization (“Pre-ischemia”) and at the end of reperfusion (“Post-ischemia”) and are expressed as mean ± SEM. 
*p < 0.05; **p < 0.01 vs. respective controls, (n = 8 per group).
Coronary flow (ml/min) EDP (mmHg) HR (beats/min)
Pre‑ischemia Post‑ischemia Pre‑ischemia Post‑ischemia Pre‑ischemia Post‑ischemia
Control 10 ± 2.3 8.2 ± 1.3 14 ± 0 33 ± 5 200 ± 12 240 ± 18
 +5 µM lactacystin 8.4 ± 1 7.5 ± 1.5 10 ± 1 29 ± 7 235 ± 8 278 ± 14
 +10 µM MG-132 12 ± 1 8 ± 2.4 11 ± 2 31 ± 2 236 ± 10 268 ± 15
High glucose 11.2 ± 1.8 6 ± 1.5 8 ± 3 65 ± 7* 347 ± 13* 244 ± 9
 +5 µM lactacystin 10 ± 2.3 8.2 ± 1.3 14 ± 0 33 ± 5** 355 ± 8 248 ± 12
 +10 µM MG-132 9 ± 2 11.2 ± 0.6* 15 ± 3 26 ± 7*** 306 ± 10 288 ± 8
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For the current study, high glucose exposure dimin-
ished myocardial SOD1, but not SOD2 expression lev-
els following ischemia–reperfusion (Fig.  8). Myocardial 
TNF-α expression was also significantly elevated while 
IkBα levels remained unaltered (vs. baseline glucose con-
ditions) following ischemia–reperfusion in the presence 
of high glucose (Fig. 9). Due to the interplay between the 
UPS and autophagy we also investigated the effects of 
lactacystin (more specific inhibitor vs. MG-132) in this 
context. LC3-II protein levels were not altered follow-
ing ischemia–reperfusion under high glucose conditions 
(Fig.  10). However, lactacystin treatment resulted in a 
robust elevation in cardiac LC3-II expression (p < 0.001 
vs. high glucose untreated). The expression of p62 was 
not significantly altered in response to high glucose but 
was significantly increased after lactacystin administra-
tion (Fig. 10).
Discussion
This study demonstrates that both lactacystin and 
MG-132 administration elicited cardioprotection during 
ischemia–reperfusion performed under acute high glu-
cose conditions. Here initial experiments demonstrated a 
robust increase in post-ischemic myocardial UPS activi-
ties together with elevated protein expression of an E3 
ligase (MAFbx). Moreover, the proteasome inhibitor 
doses employed and the treatment duration resulted in 
partial UPS impairment together with cardioprotective 
effects.
Previous studies found decreased proteasome function 
following ischemia–reperfusion, although the underly-
ing mechanisms remain unclear (reviewed in [31]). This 
likely occurs due to higher free radical generation with 
ischemia–reperfusion, thereby leading to direct oxidative 
modification and subsequent attenuation of proteasome 
Fig. 6 Comparative analysis of UPS inhibition on contractile function during ischemia–reperfusion. Isolated rat hearts were perfused under high 
glucose conditions (33 mM glucose) vs. controls (11 mM glucose) for 60 min and subsequently subjected to 20 min of global ischemia, followed 
by 60 min of reperfusion. Either 5 μM lactacystin or 10 μM MG-132 was added during the first 20 min of reperfusion. a Left ventricular developed 
pressure (LVDP) (% recovery) at baseline glucose levels (11 mM), and b with high glucose (33 mM). Rate pressure product (RPP) (% recovery) at 
baseline glucose levels (c), and d under high glucose conditions. Values are expressed as mean ± SEM (n = 8). *p < 0.05, **p < 0.01, ***p < 0.001 vs. 
respective controls.
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function [18, 31]. In agreement, we detected increased 
proteasome activities in rat hearts subjected to ischemia–
reperfusion performed under baseline glucose conditions 
vs. pre-ischemic hearts (data not shown). However, with 
hyperglycemia excess oxidative stress triggers higher UPS 
activity to help degrade and remove damaged proteins. 
For example, we recently reported increased cardiac 
superoxide levels together with decreased SOD activity 
following ischemia–reperfusion performed under high 
glucose perfusion conditions [21, 22]. These findings are 
consistent with other studies demonstrating higher UPS 
activity in diabetic mouse hearts [15], streptozotocin-
infarcted rat hearts and diabetic patients suffering from 
unstable angina [16]. What about the functional effects of 
proteasome inhibition with ischemia–reperfusion under 
hyperglycemic conditions? This study shows—for the 
first time as far as we are aware—that both lactacystin 
and MG-132 administration triggered cardioprotective 
effects with ischemia–reperfusion performed under such 
conditions. This is in agreement with previous findings 
showing that high glucose levels trigger myocardial oxi-
dative stress and apoptosis in parallel with impaired con-
tractile function [22].
The effects observed under baseline glucose condi-
tions are consistent with earlier research establishing 
that proteasome inhibition results in cardioprotection 
with ischemia–reperfusion [17, 32–34]. Although both 
beneficial and detrimental effects were observed with 
proteasome inhibition, the collective data indicate that car-
dioprotection with ischemia–reperfusion occurs only with 
acute drug administration [31]. Moreover, the outcomes 
of UPS inhibition are strongly dose- and time-depend-
ent with lower, non-toxic doses likely upregulating anti-
oxidant defenses and exerting anti-inflammatory effects, 
while higher doses and chronic treatment may result in 
damaging consequences on protein turnover and cell 
death [31]. This may also depend on distinct intracellular 
sub-compartments, with some suggesting that beneficial 
effects may be due to the inhibition of proteasomal activ-
ity within the non-cardiomyocyte compartment where it 
may exert anti-inflammatory effects [35]. In support, oth-
ers found that moderate cardiomyocyte-restricted pro-
teasome inhibition exacerbated ischemia–reperfusion 
injury in mouse hearts [36]. Further studies are, however, 
required to investigate these intriguing possibilities.
The comparative analyses performed establish that 
MG-132 administration lead to greater cardioprotec-
tion compared to lactacystin. We are unclear regarding 
the underlying mechanism(s) whereby MG-132 resulted 
in such a striking improvement in cardiac function. As 
indicated before, proteasome inhibitor dose and treat-
ment duration are crucial parameters that may affect 
functional outcomes and we therefore cannot exclude 
the possibility that lower lactacystin dosages could 
potentially result in enhanced cardioprotection. Lacta-
cystin is also considered a more specific inhibitor than 
MG-132 and it is therefore possible that the superiority 
of MG-132 may be due to non-UPS-related effects. For 
example, MG-132 can exert additional effects on calpains 
and cathepsins [37] and also protect cardiomyocytes 
from injury through the inhibition of NF-kB and down-
regulation of transforming growth factor beta 1 (TGFβ1) 
[38]. As MG-132 significantly augmented coronary flow, 
it is possible that it may also exert advantageous effects 
on cardiac endothelial cells. In support, an in vitro study 
found that low-dose proteasome inhibition upregulated 
endothelial nitric oxide synthase expression and activity 
together with improved endothelial function [39]. This 
may therefore lead to increased oxygen supply to the 
myocardium resulting in improved post-ischemic func-
tion [40].
Fig. 7 UPS inhibition attenuates infarct size. Isolated rat hearts were 
perfused under high glucose conditions (33 mM) vs. controls (11 mM) 
for 60 min and thereafter subjected to regional ischemia as earlier 
described. UPS inhibitors (5 μM lactacystin or 10 μM MG-132) were 
administered for the first 20 min of the 2-h reperfusion period. a 
Infarct size/area at risk (%) following lactacystin administration and 
b infarct size/area at risk (%) following MG-132 treatment under 
baseline vs. high glucose perfusion conditions. Values are expressed 
as mean ± SEM (n = 8). *p < 0.05, **p < 0.01, ***p < 0.001 vs. respec-
tive controls.
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To gain a better understanding of the mechanisms 
whereby proteasome inhibitors elicit cardioprotection, 
we assessed whether it exhibits anti-oxidant and/or anti-
inflammatory properties in our experimental system. It 
is well established that myocardial ischemia–reperfusion 
is associated with increased oxidative stress resulting in 
cell death [41, 42]. For example, we recently reported that 
several markers of myocardial oxidative stress were sig-
nificantly increased in our experimental model [21, 22]. 
Of note, high glucose availability leads to oxidative stress 
due to an imbalance in terms of free radical production 
and intracellular anti-oxidant defenses [43–45]. For the 
current study high glucose exposure diminished myo-
cardial SOD1, but not SOD2 expression levels follow-
ing ischemia–reperfusion. Both lactacystin and MG-132 
administration resulted in higher cardiac SOD1 and 
SOD2 protein levels and this is likely a key mechanism 
to detoxify increased free radical levels. Although we are 
unclear regarding the transcriptional modulators impli-
cated in this process, the basic leucine zipper transcrip-
tion factor, nuclear factor-erythroid 2-related factor 2 
(Nrf2), is a strong candidate as it is a known UPS target 
[46, 47]. It is likely that UPS inhibition in our experimen-
tal system attenuates Nrf2 ubiquitination and subsequent 
degradation, thereby increasing its stability and translo-
cation to the nucleus for activation of target anti-oxidant 
genes [48–50].
The effects of proteasome inhibition on myocardial 
inflammation were investigated by evaluating TNF-α 
peptide levels and NFkβ activation. For the latter, we 
determined myocardial IkBα levels—a UPS target—that 
when bound to NFκβ in the cytosol prevents its trans-
location to the nucleus and the subsequent activation 
of target genes such as TNF-α. Here TNF-α expression 
Fig. 8 UPS inhibition enhances anti-oxidant defenses during ischemia–reperfusion. Isolated rat hearts were perfused under high glucose condi-
tions (33 mM) vs. controls (11 mM) for 60 min and subjected to global ischemia as earlier described ± addition of 5 μM lactacystin or 10 μM 
MG-132 during the first 20 min of reperfusion. Western blot analysis for: a SOD1 and b SOD2 with lactacystin treatment; c SOD1 and d SOD2 with 
MG-132 administration. We employed β-actin as loading control. Values are expressed as mean ± SEM (n ≥ 4). *p < 0.05, **p < 0.01, ***p < 0.001 vs. 
respective controls.
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was significantly elevated while IkBα levels remained 
unaltered following ischemia–reperfusion in the pres-
ence of high glucose. Lactacystin administration blunted 
the TNF-α spike under baseline and high glucose condi-
tions, while this effect was not observed with MG-132. 
However, IkBα levels were significantly higher following 
lactacystin and MG-132 administration. As lactacystin 
is a more potent proteasome inhibitor than MG-132, 
this suggests that its cardioprotective effects are more 
strongly linked to the attenuation of UPS-mediated 
induction of inflammatory pathways. In support, a dis-
proportionately elevated UPS can lead to NFκβ activa-
tion, thereby resulting in downstream transcriptional 
effects and the establishment of a pro-inflammatory 
milieu with hyperglycemia and/or ischemia [16]. Thus 
these data establish that the strong pro-inflammatory 
effect triggered in response to ischemia–reperfusion 
and hyperglycemia can be blunted by partial proteasome 
inhibition.
Due to the interplay between the UPS and autophagy 
we also investigated the effects of lactacystin (more spe-
cific inhibitor vs. MG-132) in this context. LC3-II levels 
increased while there was also a significant decrease in 
p62 expression, indicating greater autophagic flux. Here 
p62 can shuttle ubiquitinated proteins not removed by 
the UPS to the autophagic clearance system [51], thus 
serving as an adapter that is able to interact with both the 
UPS and autophagic machinery to eventually help with 
the degradation of misfolded and damaged proteins [52]. 
These data are consistent with others demonstrating that 
low dose proteasome inhibitor treatment (reducing chy-
motrypsin-like activity to ~46%) increased myocardial 
autophagy [53]. Lower p62 levels would indicate greater 
clearance and uptake of damaged proteins by cardiac 
autophagosomes. Thus with UPS inhibition there is an 
upregulation of autophagy following ischemia–reperfu-
sion under high glucose conditions, likely an adaptive 
mechanism that assists with the removal of misfolded 
Fig. 9 Decreased expression of inflammatory markers following UPS inhibition with ischemia–reperfusion. Isolated rat hearts were perfused under 
high glucose conditions (33 mM) vs. controls (11 mM) and subjected to global ischemia and reperfusion ± 5 μM lactacystin or 10 μM MG-132 
treatment for the first 20 min of the reperfusion period. Western blot analysis for: a TNF-α and b IkBα with lactacystin treatment; c TNF-α and d 
IkBα with MG-132 administration. We employed β-actin as loading control. Values are expressed as mean ± SEM (n ≥ 4). *p < 0.05, **p < 0.01, 
***p < 0.001 vs. respective controls.
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and damaged proteins. This is in agreement with others 
reporting that experimentally-induced upregulation of 
autophagy was linked to improved heart function in dia-
betic mice [54].
Limitations of study
For the proteasome activity assays we did not employ 
proteasome inhibitors and the data here presented may 
also contain contributions from non-proteasomal pro-
teases. Thus it is possible that the degree of proteasomal 
inhibition could be an underestimation, although this 
should not affect our relative comparisons.
Conclusions
This study established that partial proteasome inhibition 
elicits cardioprotection in hearts exposed to ischemia–
reperfusion with acute simulated hyperglycemia. Our 
findings also show three major protective effects, i.e. (a) 
enhancing myocardial anti-oxidant defences, (b) attenu-
ating inflammation, and (c) increasing the autophagic 
response. These data are encouraging as it could lead to 
the development of novel therapeutic interventions that 
may help treat individuals burdened with hyperglycemia 
and suffering associated cardiovascular complications 
such as an AMI.
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